Active Biotech AB Year-end report January - December 2012

14 februari 2013 Events for the full year 2012 Laquinimod * Phase III data presented at the AAN (64th Annual Meeting of the American Academy of Neurology) * Application submitted for regulatory approval in the EU, milestone payment of USD 5 M from Teva * Teva initiates a Phase III study in multiple sclerosis (the CONCERTO study) in the US * Positive Crohn's Phase II data presented at the UEGW conference * Teva expands the clinical development program to encompass new indications TASQ * EUR 10 M milestone payment from Ipsen upon 600 patients enrolled in Phase III study * overall survival data from Phase II study presented * biomarker data presented at the ESMO conference * Ipsen initiated two new Phase II trials; a "switch maintenance" in prostate cancer and a second study into additional cancer forms * Phase III study fully enrolled (1,245 patients); milestone payment of EUR 10 M from Ipsen ANYARA * Phase II/III study in renal cell cancer concluded *  Results presented during Q1, 2013:  - study did not achieve primary clinical endpoint  - doubling of progression free survival and OS in 25 % of patients  - planning of the continued clinical development ongoing 57-57 * clinical trial of systemic sclerosis/scleroderma concluded ISI * focus on patent submissions H1 2013 * project proceeds as planned            Oct - Dec            Jan - Dec  (MSEK) 2012 2011 2012 2011 ---------------------------------------------------------------------------- *      Net sales 91.5 3.3 227.9 234.6 *      Operating profit/loss 5.5 -94.7 -163.2 -100.9 *      Net profit/loss  0.1 -93.2 -175.0 -94.5 *      Profit/loss per share (SEK)  0.00 -1.35 -2.54 -1.38 For further information, please contact: Tomas Leanderson, President and CEO Tel: +46 (0)46 19 20 95 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 (0)46 19 20 00, Fax +46 (0)46 19 11 00 This report is also available at www.activebiotech.com Active Biotech AB Year-end report Jan-Dec 2012: http://hugin.info/1002/R/1678129/547591.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Active Biotech via Thomson Reuters ONE [HUG#1678129]